Following Array Biopharma Inc (NASDAQ:ARRY) reporting positive top line results from part 2 of a late-stage study of its combo treatment candidate for metastatic and BRAF-mutant melanoma, Leerink ...

ARRAY BIOPHARMA ($ARRY) posted quarterly earnings results on Tuesday, May 6th. The company reported earnings of $0.13 per share, beating estimates of $0.09 by $0.04 ...

Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. Array BioPharma ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. So what: Normally ...

Co announces new Phase 1 clinical data on its M.E.K inhibitor, ARRY-162, and its p38 inhibitor, ARRY-797. Array presented preliminary information on its M.E.K inhibitor, ARRY-162, from both a single ...